Advances in Focused Ultrasound for the Treatment of Brain Tumors

Rao, Rohan; Patel, Anjali; Hanchate, Kunal; Robinson, E. A.; Edwards, A. David; Shah, Sanjit; Higgins, Dominique; Haworth, Kevin J.; Lucke‐Wold, Brandon; Krummel, Daniel Pomeranz; Sengupta, Soma

doi:10.3390/tomography9030090

Cited by 4 publications

(1 citation statement)

References 117 publications

(169 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, several ultrasound devices are FDA approved, such as Sonablate, Ablatherm, Focal-One, Tulsa-pro ® [ 184 ], and Edison TM [ 185 ] for HIFU. Additionally, Exablate, NaviFUS ® , and Sonocloud1/9 ® are typically used for UTMC to enhance drug delivery [ 186 ]. Sonalleve [ 187 ] and Sonotherm [ 188 ] are other FDA-approved devices used for HT.…”

Section: Translational Challenges and Outlookmentioning

confidence: 99%

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Jahangiri,

2024

Pharmaceutics

View full text Add to dashboard Cite

Despite spectacular clinical successes across several cancer types, immune checkpoint inhibition is effective only in subgroups of patients and suffers from significant systemic toxicities, highlighting the need to understand and locally overcome the mechanisms of therapeutic resistance. Similarly to other therapeutics, immunotherapies face delivery challenges (for example, antibodies need to reach their targets) and immunological barriers that are unique to solid tumors and their microenvironment. Interestingly, focused ultrasound (FUS), with or without microbubbles, which has been shown to enhance gene and drug delivery, notably in oncology, has been recently found to trigger immunological responses. In recent years, there has been a strong emphasis on understanding the biological and immunological effects of FUS for cancer therapy, and FUS is now emerging as an approach that can improve cancer immunotherapy. We herein review: (1) the immunological barriers implicated in ICI resistance; (2) the fundamentals of FUS +/− MB and the current knowledge on leveraging FUS +/− MB bioeffects for improving ICI therapy efficacy; (3) the immune profile of tumor models that have been successfully treated with FUS and ICI; and finally, (4) we discuss the challenges ahead for translating FUS and MB treatments to the clinic, highlighting the exciting perspectives for this new research area.

show abstract

Section: Translational Challenges and Outlookmentioning

confidence: 99%

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Jahangiri,

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Ultrasound-enabled SIMO Channel for Targeted Brain Cancer Chemotherapy

Zoofaghari,

Damrath,

Veletić

et al. 2024

ICC 2024 - IEEE International Conference on Communications

View full text Add to dashboard Cite

A Scoping Review of Focused Ultrasound Enhanced Drug Delivery for Across the Blood–Brain Barrier for Brain Tumors

Young,

Viña-González,

de Toledo Aguiar

et al. 2024

Operative Neurosurgery

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Previous mechanisms of opening the blood–brain barrier (BBB) created a hypertonic environment. Focused ultrasound (FUS) has recently been introduced as a means of controlled BBB opening. Here, we performed a scoping review to assess the advances in drug delivery across the BBB for treatment of brain tumors to identify advances and literature gaps. METHODS: A review of current literature was conducted through a MEDLINE search inclusive of articles on FUS, BBB, and brain tumor barrier, including human, modeling, and animal studies written in English. Using the Rayyan platform, 2 reviewers (J.P and C.Y) identified 967 publications. 224 were chosen to review after a title screen. Ultimately 98 were reviewed. The scoping review was designed to address the following questions: (1) What FUS technology improvements have been made to augment drug delivery for brain tumors? (2) What drug delivery improvements have occurred to ensure better uptake in the target tissue for brain tumors? RESULTS: Microbubbles (MB) with FUS are used for BBB opening (BBBO) through cavitation to increase its permeability. Drug delivery into the central nervous system can be combined with MB to enhance transport of therapeutic agents to target brain tissue resulting in suppression of tumor growth and prolonging survival rate, as well as reducing systemic toxicity and degradation rate. There is accumulating evidence demonstrating that drug delivery through BBBO with FUS-MB improves drug concentrations and provides a better impact on tumor growth and survival rates, compared with drug-only treatments. CONCLUSION: Here, we review the role of FUS in BBBO. Identified gaps in the literature include impact of tumor microenvironment and extracellular space, improved understanding and control of MB and drug delivery, further work on ideal pharmacologics for delivery, and clinical use.

show abstract

Advances in Focused Ultrasound for the Treatment of Brain Tumors

Cited by 4 publications

References 117 publications

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Ultrasound-enabled SIMO Channel for Targeted Brain Cancer Chemotherapy

A Scoping Review of Focused Ultrasound Enhanced Drug Delivery for Across the Blood–Brain Barrier for Brain Tumors

Contact Info

Product

Resources

About